Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs will be updated July 1, 2021:
Effective August 1, 2021:
- Acute Migraine Agents
- Alpha-1 Proteinase Inhibitors
- Antidepressant Agents
- Cannabidiol
- Coagulation Factor X
- Galafold (migalastat)
- Hetlioz (Previously Circadian Rhythm Disorder)
- Jynarque
- Lysosomal Storage Disorders
- Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors
- Peanut Allergy
- Substrate Reduction Therapy
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.
Institutional Providers
Professional Providers